Physician profile
Robin Hammack
NPI 1881036218
$10,866.80
in general payments reported to CMS, 2019-2025
69 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,325 · 2022: $1,968 · 2023: $2,326 · 2024: $2,687 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,504 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,503.92 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $790.20 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $663.99 | 2021-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $638.47 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Gilead Sciences, INC. | $622.78 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $568.84 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $550.35 | 2021-2025 | Enhertu, Injectafer |
| Incyte Corporation | $509.06 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $443.57 | 2022-2025 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $435.01 | 2021-2025 | Darzalex, Tecvayli, Imbruvica |
| Seagen INC. | $428.21 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Pfizer INC. | $405.84 | 2021-2025 | |
| Astellas Pharma US INC | $300.71 | 2021-2025 | Padcev, Xtandi, Xospata |
| Glaxosmithkline, LLC. | $295.81 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $253.63 | 2022-2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $234.32 | 2021-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $227.53 | 2021-2025 | |
| Abbvie INC. | $222.78 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.33 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Array Biopharma INC | $200.39 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $195.46 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $165.11 | 2021-2025 | |
| Amgen INC. | $160.79 | 2021-2023 | Lumakras |
| Beigene USA, INC. | $147.63 | 2022-2025 | Brukinsa |
| Genzyme Corporation | $114.14 | 2021-2023 | |
| Deciphera Pharmaceuticals INC. | $104.61 | 2021 | |
| Beone Medicines USA, INC. | $97.32 | 2025 | Brukinsa |
| Genentech USA, INC. | $95.67 | 2022-2025 | Tecentriq, Alecensa, Rozlytrek |
| Acrotech Biopharma INC. | $94.17 | 2022-2025 | Beleodaq |
| Kite Pharma, INC. | $91.32 | 2022-2025 | Yescarta |
| Mirati Therapeutics, INC. | $85.62 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $82.32 | 2023-2025 | Monoferric |
| Pharmaessentia USA Corporation | $70.40 | 2023-2025 | Besremi |
| Exelixis INC. | $68.63 | 2024-2025 | Cabometyx |
| Tersera Therapeutics LLC | $63.38 | 2022-2023 | Zoladex |
| Rigel Pharmaceuticals, INC. | $63.30 | 2024 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.40 | 2023-2024 | Gilotrif |
| Puma Biotechnology, INC. | $61.68 | 2021-2024 | |
| Epizyme, INC. | $59.04 | 2021-2024 | Onivyde, Tazverik |
| Regeneron Healthcare Solutions, INC. | $58.82 | 2024-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $58.70 | 2021-2023 | Epkinly, Imbruvica |
| Servier Pharmaceuticals LLC | $58.19 | 2023-2024 | |
| Genmab U.S., INC. | $56.95 | 2024 | Epkinly |
| Stemline Therapeutics INC. | $55.83 | 2025 | Orserdu |
| Cti Biopharma Corp. | $51.30 | 2022-2023 | Vonjo |
| Dendreon Pharmaceuticals LLC | $50.32 | 2024 | Provenge |
| G1 Therapeutics, INC. | $45.92 | 2022-2023 | Cosela |
| Recordati_rare_diseases_inc. | $40.60 | 2023 | Panhematin, Sylvant |
| Adc Therapeutics America, INC. | $36.19 | 2021-2025 | |
| Heron Therapeutics, INC. | $34.04 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $32.80 | 2021-2025 | Ultomiris |
| Sumitomo Pharma America, INC. | $31.21 | 2024-2025 | Orgovyx |
| Legend Biotech USA INC. | $28.37 | 2025 | Carvykti |
| Taiho Oncology, INC. | $28.21 | 2021-2024 | |
| Blueprint Medicines Corporation | $28.19 | 2021-2024 | Ayvakit |
| Dova Pharmaceuticals | $28.02 | 2021 | |
| Argenx US, INC. | $25.88 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Telix Pharmaceuticals | $24.56 | 2023 | Illuccix |
| Alnylam Pharmaceuticals INC. | $23.26 | 2024 | Onpattro |
| Ge Healthcare | $22.43 | 2022 | |
| Morphosys, US INC. | $19.86 | 2023 | Monjuvi |
| Amag Pharmaceuticals, INC. | $18.13 | 2021 | |
| Emd Serono, INC. | $17.82 | 2024 | |
| Adaptive Biotechnologies Corporation | $16.36 | 2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $16.27 | 2021 | |
| Novocure INC. | $16.01 | 2025 | Optune Lua (Novottf-200t) |
| Karyopharm Therapeutics INC. | $14.67 | 2023 | Xpovio |
| Agios Pharmaceuticals, INC. | $14.64 | 2023 | Pyrukynd |
| Myovant Sciences INC. | $12.77 | 2022 | |
| Acceleron Pharma, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hammack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.